褚思梦，汉族，药物分析学博士，本科毕业于吉林大学药学院药学专业，后于南开大学攻读中药学硕士以及药物分析学博士，并获南开大学理学硕士及理学博士学位，现任天津中医药大学中药学院药理教研室专任教师。主要研究方向为基于化学生物学的中药药效成分靶标识别及作用机制研究和中药配伍理论研究，现以第一作者身份发表SCI论文4篇，合作发表SCI论文4篇，合作发表授权专利2篇。

主要代表成果：

[1] Chu Simeng, Lu Yujie, Liu Wenjuan, Jiang Min*, Bai Gang*. Ursolic acid alleviates tetrandrine-induced hepatotoxicity by competitively binding to the substrate-binding site of glutathione S-transferases. Phytomedicine. 2022.

[2] Chu Simeng, Shen Fukui, Liu Wenjuan, Jiang Min*, Bai Gang*. Sinapine targeting PLCβ3 EF hands disrupts Gαq-PLCβ3 interaction and ameliorates cardiovascular diseases. Phytomedicine. 2024.

[3] Chu Simeng, Lu Yujie, Liu Wenjuan*, Jiang Min*, Bai Gang*. Tetrandrine inhibits aldosterone synthesis by covalently targeting CYP11A1 to prevent hypertension. Frontiers In Pharmacology.2024.

[4] Chu Simeng, Jiang Min*, Bai Gang*. Sinigrin Enhanced Anti-asthmatic Effects of beta 2 Adrenergic Receptors Agonists by Regulating cAMP-Mediated Pathways. Frontiers In Pharmacology.2020.

[5] Liu Wenjuan, Li Zhenqiang, Chu Simeng, Jiang Min*, Bai Gang*. Atractylenolide-I covalently binds to CYP11B2, selectively inhibits aldosterone synthesis, and improves hyperaldosteronism. Acta Pharm Sin B. 2022.

[6] Lu Yujie, Ji Jie, Chu Simeng, Jiang Min*, Bai Gang*. CaMKII, that binds with ligustilide, as a potential drug target of Suxiao jiuxin pill, a traditional Chinese medicine to dilate thoracic aorta. Clin Transl Med. 2022.

授权专利：

[1]白钢,褚思梦,姜民,等.一种协同抑制汉防己甲素诱导的药源性肝损伤的药物组合物:CN202111543542.X[P]. CN202111543542.X.

[2]白钢,褚思梦,姜民,等.一种协同抑制醛固酮增多症的天然药物组合物:CN202111543533.0[P].CN114099494B.